跳至主要内容
临床试验/NCT00709436
NCT00709436已完成3 期

Randomized, Multiple-center, Double-blind, Placebo-controlled Study of the Safety and Analgesic Efficacy of Repeated Dosing of PMI-150 (Intranasal Ketamine) to Treat Acute Post-operative Pain Following Orthopedic Trauma, Injury, or Surgery.

Hospira, now a wholly owned subsidiary of Pfizer16 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2008年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
250
试验地点
16
主要终点
Measures of pain intensity difference

研究概览

简要总结

The purpose of this research study is to evaluate the safety and analgesic efficacy of PMI-150 (intranasal ketamine) compared to placebo in patients with acute post-operative pain following orthopedic trauma, injury, or surgery.

详细描述

Patients will be randomly assigned to PMI-150 (intranasal ketamine) or placebo and will receive repeated doses and be assessed for safety and efficacy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patient is scheduled for elective orthopedic surgery or procedure

排除标准

  • patient has received an investigational drug or participated in a clinical trial within 30 days or 5 half-lives (whichever is longer) of entering this study

研究组 & 干预措施

1

Experimental

PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.

干预措施: PMI-150 (intranasal ketamine) (Drug)

2

Placebo Comparator

Placebo at time 0 and specified time points thereafter.

干预措施: Placebo (Drug)

结局指标

主要结局

Measures of pain intensity difference

时间窗: 0-6 hours

次要结局

未报告次要终点

研究者

发起方
Hospira, now a wholly owned subsidiary of Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验